SERIAL PROSTATE SPECIFIC ANTIGEN SCREENING FOR PROSTATE CANCER: A COMPUTER MODEL EVALUATES COMPETING STRATEGIES

Abstract

Under the model assumptions biannual PSA screening is a cost-effective alternative to annual PSA screening for prostate cancer. With annual screening use of an age specific bound for PSA positivity appears to reduce false-positive results and over diagnosis rates sharply relative to a bound of 4 ng./ml. while retaining most of the survival benefits.